Latest Rodenticides Stories
OAKLAND, Calif., April 7 /PRNewswire/ -- Machaon Diagnostics, California's only independent laboratory for testing bleeding and clotting disorders has launched a clinical testing service for patients that have been prescribed warfarin.
ATLANTA, March 16 /PRNewswire-FirstCall/ -- Hospitalization rates for heart patients taking warfarin, the world's most-prescribed blood thinner, dropped by approximately 30 percent when genetic information was available to doctors prescribing the drug, researchers from Medco Health Solutions, Inc.-- in association with the Medco Research Institute(TM) -- and Mayo Clinic announced today.
Children with serious intestinal problems have to be fed intravenously.
National Trauma Databank researchers find elderly patients more vulnerable to problems CHICAGO, Oct.
BOSTON and EDISON, N.J., July 15 /PRNewswire/ -- A sub-analysis of a Phase IIb multinational study(1) with edoxaban(2) - an investigational oral Factor Xa inhibitor - provides insights into why patients with non-valvular atrial fibrillation (AF) receiving edoxaban once daily (QD) experienced fewer bleeding events than patients given edoxaban twice a day (BID).
Researchers at Uppsala University, together with colleagues at the Karolinska Institute and the Sanger Institute, have now found all the genes the determine the dosage of the blood-thinning drug warfarin.
A new formula that involves gene testing could equip doctors with a better means of gauging the dosage of the common blood-thinning drug warfarin, according to a new large-scale study.
New analyses led by the University of Cincinnati (UC) show that genetic testing used to guide initial dosing of the blood-thinner warfarin may not be cost-effective for typical patients with atrial fibrillation but may be for patients at higher risk for major bleeding.
Researchers from Boston University School of Medicine (BUSM) have determined the optimal dose-management strategy to derive maximal benefit from warfarin therapy and improve patient outcomes.
ARYx Therapeutics Inc. (NASDAQ:ARYX), a biopharmaceutical company, today announced it has completed enrollment in EmbraceAC, a Phase 2/3 double-blind clinical trial comparing its oral anticoagulation therapy, ATI-5923, against the leading anticoagulant agent, warfarin.
- A political dynamiter.